US7626192B2
(en)
|
1997-05-27 |
2009-12-01 |
State of Oregon Acting by the Through the State Board of Higher Education on Behalf of the University of Oregon |
Scaffold-organized clusters and electronic devices made using such clusters
|
JP3614866B2
(ja)
*
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ,インコーポレイティド |
人工抗体ポリペプチド
|
US6818418B1
(en)
*
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
US7115396B2
(en)
*
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
AU2001249459A1
(en)
*
|
2000-03-24 |
2001-10-08 |
The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon |
Scaffold-organized clusters and electronic devices made using such clusters
|
CA2416219C
(en)
|
2000-07-11 |
2016-10-11 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
EP2141243A3
(de)
*
|
2000-10-16 |
2010-01-27 |
Brystol-Myers Squibb Company |
Proteingerüste für Antikörpermimetika und andere Bindungsproteine
|
US7598352B2
(en)
*
|
2000-11-17 |
2009-10-06 |
University Of Rochester |
Method of identifying polypeptide monobodies which bind to target proteins and use thereof
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20030082630A1
(en)
*
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
EP1318195A1
(de)
*
|
2001-12-10 |
2003-06-11 |
CatchMabs B.V. |
Ein Struktur für die Präsentation erwünschter Peptidsequenzen
|
AU2003243436A1
(en)
|
2002-06-06 |
2003-12-22 |
Shohei Koide |
Reconstituted polypeptides
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US20060205089A1
(en)
*
|
2003-04-14 |
2006-09-14 |
Montana State University |
Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
|
CN100417414C
(zh)
|
2003-04-30 |
2008-09-10 |
苏黎世大学 |
免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050164301A1
(en)
*
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
SG149004A1
(en)
|
2003-12-05 |
2009-01-29 |
Bristol Myers Squibb Co |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
GB0400122D0
(en)
*
|
2004-01-06 |
2004-02-11 |
Badrilla Ltd |
Method of quantifying binding
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
GB0417887D0
(en)
|
2004-08-11 |
2004-09-15 |
Ares Trading Sa |
Protein
|
GB0423126D0
(en)
*
|
2004-10-18 |
2004-11-17 |
Ares Trading Sa |
Protein
|
GB0426960D0
(en)
*
|
2004-12-08 |
2005-01-12 |
Ares Trading Sa |
TGR-3 like protein receptor
|
US20080254451A1
(en)
*
|
2004-12-28 |
2008-10-16 |
Ares Trading S.A. |
Compositions and Methods for Treating Schizophrenia and Related Disorders
|
US7749694B2
(en)
|
2004-12-31 |
2010-07-06 |
The Regents Of The University Of California |
C-type lectin fold as a scaffold for massive sequence variation
|
KR101404512B1
(ko)
|
2005-01-05 |
2015-01-29 |
에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. |
상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역
|
GB0504767D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
WO2007062676A1
(en)
|
2005-12-01 |
2007-06-07 |
B.R.A.H.M.S. Aktiengesellschaft |
Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
|
US8445639B2
(en)
*
|
2006-05-15 |
2013-05-21 |
Avidbiotics Corporation |
Recombinant bacteriophage and methods for their use
|
JP5603070B2
(ja)
*
|
2006-05-15 |
2014-10-08 |
アビッドバイオティクス コーポレイション |
改変バクテリオシン及びその使用方法
|
US7700729B2
(en)
*
|
2006-05-15 |
2010-04-20 |
Avidbiotics Corporation |
Modified bacteriocins and methods for their use
|
CN101506227A
(zh)
*
|
2006-05-26 |
2009-08-12 |
怀卡托灵科有限公司 |
Ob折叠结构域
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
*
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
WO2008003473A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
EP2423333A1
(de)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognosemarker und therapeutische Targets für Lungenkrebs
|
WO2008048970A2
(en)
*
|
2006-10-16 |
2008-04-24 |
The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Synthetic antibodies
|
JP5238710B2
(ja)
|
2006-10-19 |
2013-07-17 |
シーエスエル、リミテッド |
インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
CA2667678A1
(en)
*
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
NZ598345A
(en)
|
2006-11-21 |
2013-09-27 |
Kalobios Pharmaceuticals Inc |
Methods of treating chronic inflammatory diseases using a gm-csf antagonist
|
EP2727936B1
(de)
|
2006-11-22 |
2016-09-07 |
Bristol-Myers Squibb Company |
Gezielte Therapeutik auf Grundlage manipulierter Proteine für Tyrosinkinaserezeptoren, einschließlich IGF-IR
|
WO2008097497A2
(en)
|
2007-02-02 |
2008-08-14 |
Adnexus, A Bristol-Myers Squibb R & D Company |
Vegf pathway blockade
|
WO2008103378A2
(en)
|
2007-02-20 |
2008-08-28 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
CN101641115B
(zh)
|
2007-03-08 |
2013-04-24 |
卡罗拜奥斯制药公司 |
用于实体瘤治疗的EphA3抗体
|
NZ579594A
(en)
|
2007-03-12 |
2012-03-30 |
Esbatech Alcon Biomed Res Unit |
Sequence based engineering and optimization of single chain antibodies
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2008144345A2
(en)
|
2007-05-17 |
2008-11-27 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
|
EP2162540A2
(de)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
|
WO2009000099A2
(en)
|
2007-06-25 |
2008-12-31 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
EP2164961B1
(de)
|
2007-06-25 |
2015-01-07 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
|
EP3241842B1
(de)
|
2007-06-26 |
2024-01-31 |
F-star Therapeutics Limited |
Präsentieren von bindenden mitteln
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8680019B2
(en)
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
US20090176654A1
(en)
|
2007-08-10 |
2009-07-09 |
Protelix, Inc. |
Universal fibronectin type III binding-domain libraries
|
AU2008293986A1
(en)
*
|
2007-08-23 |
2009-03-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptogenesis
|
EP2190478B1
(de)
|
2007-08-24 |
2016-03-23 |
Oncotherapy Science, Inc. |
Dkk1-onkogen als therapeutisches ziel für krebs und diagnostischer marker
|
RU2010111120A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
|
TW200920405A
(en)
|
2007-08-24 |
2009-05-16 |
Oncotherapy Science Inc |
PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis
|
GB2453589A
(en)
*
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
AU2008319298B2
(en)
*
|
2007-10-31 |
2014-07-31 |
Medimmune, Llc |
Protein scaffolds
|
EA201000718A1
(ru)
|
2007-11-02 |
2011-06-30 |
Новартис Аг |
Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
|
EP2215115A1
(de)
*
|
2007-11-08 |
2010-08-11 |
The University of Chicago |
Molecular affinity clamp-technologie und anwendungen davon
|
CL2008003561A1
(es)
|
2007-11-30 |
2010-02-05 |
Glaxo Group Ltd |
Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
|
EA201000979A1
(ru)
*
|
2007-12-27 |
2011-02-28 |
Новартис Аг |
Улучшенные связывающие молекулы на основе фибронектина и их применение
|
ATE555131T1
(de)
|
2008-01-15 |
2012-05-15 |
Kalobios Pharmaceuticals Inc |
Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten
|
WO2009102421A2
(en)
|
2008-02-14 |
2009-08-20 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
AU2009239558B2
(en)
|
2008-04-21 |
2013-05-02 |
Bio-Rad Laboratories, Inc. |
Recombinant deamidated gliadin antigen
|
US20120021967A1
(en)
*
|
2008-04-23 |
2012-01-26 |
Arizona Board of Regents, A Body Corporate of the State Of Arizona Acting for and Behalf of Arizona |
Synthetic antibodies
|
PT2274331E
(pt)
|
2008-05-02 |
2014-02-27 |
Novartis Ag |
Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
KR20110010758A
(ko)
|
2008-05-06 |
2011-02-07 |
글락소 그룹 리미티드 |
생물학적 활성제의 캡슐화
|
PE20091931A1
(es)
|
2008-05-22 |
2009-12-31 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
DK3241843T3
(da)
|
2008-06-25 |
2021-09-06 |
Novartis Ag |
Opløselighedsoptimering af immunbindere
|
EP3629022A1
(de)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Proteinscreeningverfahren
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
EP2323695B1
(de)
|
2008-08-19 |
2018-12-05 |
Nektar Therapeutics |
Komplexe von small-interfering nukleinsäuren
|
WO2010096126A1
(en)
|
2008-10-29 |
2010-08-26 |
Bg Medicine, Inc. |
Galectin-3 immunoassay
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
RS55218B1
(sr)
|
2008-10-31 |
2017-02-28 |
Janssen Biotech Inc |
Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
US20110275535A1
(en)
|
2008-12-16 |
2011-11-10 |
Novartis Ag |
Yeast Display Systems
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
WO2010093814A1
(en)
|
2009-02-11 |
2010-08-19 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating dementia using a gm-csf antagonist
|
CA2753287A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20110305693A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Anitigen-binding constructs
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
AR075715A1
(es)
*
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
WO2010102244A1
(en)
|
2009-03-06 |
2010-09-10 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
US8067201B2
(en)
*
|
2009-04-17 |
2011-11-29 |
Bristol-Myers Squibb Company |
Methods for protein refolding
|
MA33279B1
(fr)
|
2009-04-27 |
2012-05-02 |
Novartis Ag |
Compositions et procédés pour l'augmentation de la croissance des muscles
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
WO2010127186A1
(en)
|
2009-04-30 |
2010-11-04 |
Prognosys Biosciences, Inc. |
Nucleic acid constructs and methods of use
|
WO2011012646A2
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
EP2464657B1
(de)
|
2009-08-10 |
2015-04-01 |
MorphoSys AG |
Neue screening-verfahren zur identifizierung von antikörpern und deren fragmente, die ein antigen mit enzymatischer aktivität binden
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
JP5733784B2
(ja)
*
|
2009-09-24 |
2015-06-10 |
国立大学法人埼玉大学 |
cDNA/mRNA−タンパク質連結体の効率的合成法
|
EP2494070A2
(de)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Verfahren zur krebsbehandlung bei patienten mit igf-1r-hemmer-resistenz
|
ES2860453T3
(es)
|
2009-10-30 |
2021-10-05 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
AU2010326024A1
(en)
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
NO2516702T3
(de)
|
2009-12-23 |
2018-08-18 |
|
|
JP5850860B2
(ja)
|
2010-01-28 |
2016-02-03 |
グラクソ グループ リミテッドGlaxo Group Limited |
Cd127結合タンパク質
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
KR20130010461A
(ko)
|
2010-02-18 |
2013-01-28 |
브리스톨-마이어스 스큅 컴퍼니 |
Il―23에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US10787701B2
(en)
|
2010-04-05 |
2020-09-29 |
Prognosys Biosciences, Inc. |
Spatially encoded biological assays
|
US20190300945A1
(en)
|
2010-04-05 |
2019-10-03 |
Prognosys Biosciences, Inc. |
Spatially Encoded Biological Assays
|
PL2556171T3
(pl)
|
2010-04-05 |
2016-04-29 |
Prognosys Biosciences Inc |
Oznaczenia biologiczne kodowane przestrzennie
|
KR20130056871A
(ko)
|
2010-04-13 |
2013-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Pcsk9에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
|
BR112012026003B1
(pt)
|
2010-04-13 |
2022-03-15 |
Medimmune, Llc |
Estrutura multimérica recombinante específica trail r2, seu uso, bem como composição
|
AU2011245225B2
(en)
|
2010-04-30 |
2015-09-17 |
Janssen Biotech, Inc. |
Stabilized fibronectin domain compositions, methods and uses
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
KR20130036012A
(ko)
|
2010-05-07 |
2013-04-09 |
에프. 호프만-라 로슈 아게 |
생체외 세포의 검출을 위한 진단 방법
|
CN103180339B
(zh)
|
2010-05-26 |
2016-04-27 |
百时美施贵宝公司 |
具有改善的稳定性的基于纤连蛋白的支架蛋白质
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
EP2635304B1
(de)
|
2010-11-05 |
2017-03-08 |
Morphotek, Inc. |
Folatrezeptor-alpha als diagnostischer und prognostischer marker für folatrezeptor- alpha-exprimierende karzinome
|
PT2643352T
(pt)
|
2010-11-23 |
2018-08-01 |
Glaxo Group Ltd |
Proteínas de ligação a antigénio para a oncostatina m (osm)
|
US20130236467A1
(en)
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
CN103380143B
(zh)
|
2010-12-22 |
2016-01-06 |
百时美施贵宝公司 |
结合il-23的基于纤连蛋白的支架结构域蛋白质
|
WO2012139110A2
(en)
|
2011-04-08 |
2012-10-11 |
Prognosys Biosciences, Inc. |
Peptide constructs and assay systems
|
GB201106254D0
(en)
|
2011-04-13 |
2011-05-25 |
Frisen Jonas |
Method and product
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
EP2710382B1
(de)
|
2011-05-17 |
2017-10-18 |
Bristol-Myers Squibb Company |
Verbesserte verfahren zur auswahl von bindungsproteinen
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
ES2953190T3
(es)
|
2011-05-27 |
2023-11-08 |
Glaxo Group Ltd |
Proteínas de unión a BCMA (CD269/TNFRSF17)
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
CA2840650C
(en)
|
2011-06-29 |
2019-08-20 |
Affinity Biosciences Pty Ltd |
Method of protein display
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
EP3939613A1
(de)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutikum für autoimmunerkrankungen mit pd-1-agonist
|
EP4151785A1
(de)
|
2011-09-27 |
2023-03-22 |
Janssen Biotech, Inc. |
Auf fibronektin typ iii repeat basierende proteingerüste mit alternativen bindeoberflächen
|
AU2012323316B2
(en)
|
2011-10-11 |
2017-08-10 |
Viela Bio, Inc. |
CD40L-specific Tn3-derived scaffolds and methods of use thereof
|
EP2766497A1
(de)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Verfahren zur auswahl und behandlung von krebs bei patienten mit igf-1r/ir-hemmern
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
RU2014122602A
(ru)
|
2011-11-04 |
2015-12-10 |
Новартис Аг |
Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
|
RU2662671C2
(ru)
|
2011-11-16 |
2018-07-26 |
Адреномед Аг |
АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ
|
EP2780717B1
(de)
|
2011-11-16 |
2016-12-21 |
sphingotec GmbH |
Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
|
CA2856136A1
(en)
|
2011-11-16 |
2013-05-23 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
RS58340B1
(sr)
|
2011-11-16 |
2019-03-29 |
Adrenomed Ag |
Antitelo na adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za regulisanje ravnoteže tečnosti u pacijentu koji ima hroničnu ili akutnu bolest
|
HUE045940T2
(hu)
|
2011-11-16 |
2020-01-28 |
Adrenomed Ag |
Adrenomedullinhoz kötõdõ anti-adrenomedullin (ADM) antitest vagy anti-ADM antitest fragmens vagy anti-ADM nem-Ig váz egy páciens akut betegségének vagy akut állapotának kezelésében a keringés stabilizálására történõ alkalmazásra
|
SG10202006318TA
(en)
|
2011-11-16 |
2020-08-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
CN104254777B
(zh)
|
2011-12-05 |
2016-08-24 |
伯乐实验室公司 |
重组脱酰胺化麦醇溶蛋白抗原
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
AU2012356170B2
(en)
|
2011-12-21 |
2016-06-16 |
Novartis Ag |
Compositions and methods for antibodies targeting Factor P
|
NZ626620A
(en)
|
2012-01-10 |
2016-07-29 |
Biogen Ma Inc |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
WO2013113696A1
(en)
|
2012-01-30 |
2013-08-08 |
Vib Vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
PT2814843T
(pt)
|
2012-02-13 |
2020-06-18 |
Agency Science Tech & Res |
Anticorpos monoclonais humanos neutralizantes de il-b
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
ES2879387T3
(es)
|
2012-09-13 |
2021-11-22 |
Bristol Myers Squibb Co |
Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
|
TR201809001T4
(tr)
|
2012-10-02 |
2018-07-23 |
Sphingotec Gmbh |
Böbrek fonksiyonunu teşhis etmek veya izlemek veya böbrek fonksiyonu bozukluğunu teşhis etmek için bir usul.
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
PT2928921T
(pt)
|
2012-12-05 |
2021-04-06 |
Novartis Ag |
Composições e métodos para anticorpos que visam epo
|
CA2897327A1
(en)
|
2013-01-08 |
2014-07-17 |
Sphingotec Gmbh |
Fasting levels of growth hormone as a predictive marker of cardiovascular risk
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
ES2814558T3
(es)
|
2013-02-06 |
2021-03-29 |
Bristol Myers Squibb Co |
Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
|
UY35315A
(es)
|
2013-02-08 |
2014-09-30 |
Novartis Ag |
Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
|
ES2645634T3
(es)
|
2013-02-12 |
2017-12-07 |
Bristol-Myers Squibb Company |
Métodos de replegado de proteínas a elevado pH
|
AU2014223824B2
(en)
|
2013-02-28 |
2020-02-27 |
Albert Einstein College Of Medicine, Inc. |
Tuberculosis biomarkers and uses thereof
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
WO2014141064A1
(en)
|
2013-03-13 |
2014-09-18 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
US9005901B2
(en)
|
2013-03-15 |
2015-04-14 |
Abbott Laboratories |
Assay with internal calibration
|
CN111233978A
(zh)
|
2013-03-15 |
2020-06-05 |
普罗格诺西斯生物科学公司 |
用于检测肽/mhc/tcr结合的方法
|
US9157910B2
(en)
|
2013-03-15 |
2015-10-13 |
Abbott Laboratories |
Assay with increased dynamic range
|
EP2970426B1
(de)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
|
US10598674B2
(en)
|
2013-03-20 |
2020-03-24 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
CN105143250B
(zh)
*
|
2013-05-10 |
2020-11-03 |
北京华金瑞清生物医药技术有限公司 |
一种改造非抗体类蛋白产生结合分子的方法及其产品和一种长效glp-1受体激动剂
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US9868979B2
(en)
|
2013-06-25 |
2018-01-16 |
Prognosys Biosciences, Inc. |
Spatially encoded biological assays using a microfluidic device
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
US10059937B2
(en)
|
2013-09-27 |
2018-08-28 |
The Board Of Trustees Of The University Of Illinois |
Method and kit for generating high affinity binding agents
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
US10288608B2
(en)
|
2013-11-08 |
2019-05-14 |
Prognosys Biosciences, Inc. |
Polynucleotide conjugates and methods for analyte detection
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
JP6644701B2
(ja)
|
2014-03-20 |
2020-02-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
安定化したフィブロネクチンベーススキャフォールド分子
|
IL275497B
(en)
|
2014-03-20 |
2022-09-01 |
Bristol Myers Squibb Co |
Serum proteins with type iii fibronectin binding domains
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
EP3161001A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
|
US10398765B2
(en)
|
2014-07-03 |
2019-09-03 |
Yale University |
Dickkopf2 (Dkk2) inhibition suppresses tumor formation
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3174546B1
(de)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Teilmengenoptimierte chimäre antigenrezeptorhaltige t-zellen
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
EP3002589A1
(de)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
Verfahren zur stratifizierung einer frau zur hormonersatztherapie
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
HUE049982T2
(hu)
|
2014-11-14 |
2020-11-30 |
Hoffmann La Roche |
TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
|
EA037590B1
(ru)
|
2014-11-25 |
2021-04-19 |
Бристол-Майерс Сквибб Компани |
Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
|
BR112017010414A2
(pt)
|
2014-11-25 |
2018-05-15 |
Bristol-Myers Squibb Company |
métodos e composições para radiomarcação com 18f de substâncias biológicas
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
CN116869964A
(zh)
|
2014-12-24 |
2023-10-13 |
耐克西缪恩有限公司 |
用于免疫疗法的纳米颗粒组合物和方法
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
ES2955916T3
(es)
|
2015-04-10 |
2023-12-11 |
Spatial Transcriptomics Ab |
Análisis múltiplex de especímenes biológicos de ácidos nucleicos espacialmente distinguidos
|
JP6841765B2
(ja)
|
2015-04-24 |
2021-03-10 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
慢性腎疾患の発症のリスクを予測するための方法
|
AU2016252008B2
(en)
|
2015-04-24 |
2019-06-13 |
VIIV Healthcare UK (No.5) Limited |
Polypeptides targeting HIV fusion
|
EP3549606A1
(de)
|
2015-05-28 |
2019-10-09 |
Bio-rad Laboratories, Inc. |
Affinitätsliganden und entsprechende verfahren
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
EP3347377B1
(de)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
US11124791B2
(en)
|
2015-09-14 |
2021-09-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Generating recombinant affinity reagents with arrayed targets
|
KR20180056701A
(ko)
|
2015-09-23 |
2018-05-29 |
브리스톨-마이어스 스큅 컴퍼니 |
패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인
|
CN108884147B
(zh)
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
EP3356403A2
(de)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispezifische antikörper spezifisch für co-stimulierenden tnf-rezeptor
|
MX2018004157A
(es)
|
2015-10-07 |
2019-04-01 |
F Hoffmann La Roche Ag |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
|
RU2018119317A
(ru)
|
2015-10-28 |
2019-12-04 |
Йейл Юниверсити |
Гуманизированное антитело к dkk2 и его применение
|
EP3371311B1
(de)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bifunktionale chimäre proteine und verwendungen davon
|
SG10202004259PA
(en)
|
2015-11-19 |
2020-06-29 |
Asclepix Therapeutics Llc |
Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
WO2017134305A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Bispecific signaling agents and uses thereof
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
BR112018015690A2
(pt)
|
2016-02-17 |
2018-12-26 |
Novartis Ag |
anticorpos tgfbeta 2
|
EP3426278B1
(de)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Einzeldomänenantikörper gegen cd20
|
WO2017161169A1
(en)
|
2016-03-17 |
2017-09-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-py1235-met immunological binding reagent
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
JP7038353B2
(ja)
|
2016-04-13 |
2022-03-18 |
ヴィヴィア バイオテック,エス.エル |
エクスビボのbite活性化t細胞
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
JP2019520550A
(ja)
|
2016-04-21 |
2019-07-18 |
スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp3の定量方法および治療方法
|
US11312766B2
(en)
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
EP3455254B1
(de)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und einem tenascin-bindungsteil
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
CA3023881A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
WO2017210302A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Pet imaging with pd-l1 binding polypeptides
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
WO2017210598A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Compositions and methods for treating an articular disorder
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
EP3482208B1
(de)
|
2016-07-08 |
2023-04-12 |
SphingoTec GmbH |
Adrenomedullin zur beurteilung der kongestion in einer person mit akutem herzversagen
|
WO2018050902A2
(en)
|
2016-09-15 |
2018-03-22 |
Quadrucept Bio Limited |
Multimers, tetramers & octamers
|
EP3515936A1
(de)
|
2016-09-23 |
2019-07-31 |
Elstar Therapeutics, Inc. |
Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
|
AU2017339970A1
(en)
|
2016-10-04 |
2019-04-18 |
Asclepix Therapeutics, Llc |
Compounds and methods for activating Tie2 signaling
|
EP3309550A1
(de)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Verfahren zum nachweis von apolipoprotein e4
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd8a結合フィブロネクチンiii型ドメイン
|
EP3554561B1
(de)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137-bindende fibronectin-typ-iii-domänen
|
CN110167962B
(zh)
|
2016-12-16 |
2024-06-07 |
艾德里诺医药公司 |
用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
MX2019009255A
(es)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Proteínas quiméricas dirigidas y sus usos.
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
EP3601346A1
(de)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
MA49039A
(fr)
|
2017-04-04 |
2020-02-12 |
Hoffmann La Roche |
Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
US20200071417A1
(en)
|
2017-04-19 |
2020-03-05 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
AU2018276361A1
(en)
|
2017-05-30 |
2019-12-05 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
|
EP3630836A1
(de)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
|
CN111065407A
(zh)
*
|
2017-06-16 |
2020-04-24 |
普罗特利卡公司 |
纤连蛋白结合结构域嵌合抗原受体及其使用方法
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
EP3661536A4
(de)
|
2017-08-03 |
2021-07-21 |
Asclepix Therapeutics, Inc. |
Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
MX2020003538A
(es)
|
2017-09-25 |
2020-07-29 |
Adrenomed Ag |
Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos.
|
US20220268761A1
(en)
|
2017-10-18 |
2022-08-25 |
Adrenomed Ag |
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
|
WO2019081504A1
(en)
|
2017-10-24 |
2019-05-02 |
Sphingotec Gmbh |
SENENOPROTEIN P FOR PREDICTING A FIRST CARDIOVASCULAR EVENT
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
CN111542548A
(zh)
|
2017-10-25 |
2020-08-14 |
4Teen4制药有限公司 |
针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
|
EP3703746A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Neuartige antigenbindende moleküle mit ligandentrimer der tnf-familie
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
KR20200087236A
(ko)
|
2017-11-22 |
2020-07-20 |
노파르티스 아게 |
항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EP3728310A1
(de)
|
2017-12-18 |
2020-10-28 |
VIIV Healthcare UK (No.5) Limited |
Antigenbindende polypeptide
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
MX2020008208A
(es)
|
2018-02-05 |
2020-11-09 |
Orionis Biosciences Inc |
Agentes de unión a fibroblastos y uso de estos.
|
SG11202006686SA
(en)
|
2018-02-08 |
2020-08-28 |
Sphingotec Gmbh |
Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
US11680091B2
(en)
|
2018-02-23 |
2023-06-20 |
The University Of Chicago |
Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
EP3569614A1
(de)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
EP3586865A1
(de)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
CN112424228A
(zh)
|
2018-07-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
EP3823979A1
(de)
*
|
2018-07-20 |
2021-05-26 |
AiCuris GmbH & Co. KG |
Verfahren zum screening und zur identifizierung von wirkstoffen, die den nuklearen austrittskomplex von herpesviren hemmen oder modulieren
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
JP7221379B2
(ja)
|
2018-10-01 |
2023-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗fapクローン212を含む二重特異性抗原結合分子
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020131935A1
(en)
|
2018-12-18 |
2020-06-25 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
SG11202105176QA
(en)
|
2018-12-20 |
2021-06-29 |
Sphingotec Gmbh |
Selenoprotein p in heart failure
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
WO2020128039A2
(en)
|
2018-12-21 |
2020-06-25 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
SG11202108281UA
(en)
|
2019-02-15 |
2021-08-30 |
Integral Molecular Inc |
Claudin 6 antibodies and uses thereof
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Pd-1/cd3二重特異性タンパク質による血液がん治療
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
AU2020328194A1
(en)
|
2019-08-15 |
2022-03-17 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
CN114556100A
(zh)
|
2019-08-30 |
2022-05-27 |
4Teen4制药有限公司 |
用于治疗休克的疗法指引和/或疗法监测
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
JP2022551204A
(ja)
|
2019-10-14 |
2022-12-07 |
アロ・バイオセラピューティクス・カンパニー |
Cd71結合フィブロネクチンiii型ドメイン
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
EP4084821A4
(de)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
EP3871689A1
(de)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
|
AU2021227279A1
(en)
|
2020-02-27 |
2022-10-20 |
Adrenomed Ag |
Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock
|
CA3172349A1
(en)
|
2020-02-27 |
2021-09-02 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
|
US20230104578A1
(en)
|
2020-02-27 |
2023-04-06 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
WO2021174045A1
(en)
|
2020-02-28 |
2021-09-02 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
CA3112051A1
(en)
|
2020-03-16 |
2021-09-16 |
Sphingotec Gmbh |
Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
|
CN115769076A
(zh)
|
2020-03-16 |
2023-03-07 |
4Teen4制药有限公司 |
感染冠状病毒的患者中的dpp3
|
EP3922993A1
(de)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 bei patienten, die mit coronavirus infiziert sind
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
US20220017637A1
(en)
|
2020-06-23 |
2022-01-20 |
Hoffmann-La Roche Inc. |
Agonistic cd28 antigen binding molecules targeting her2
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
JP2023549316A
(ja)
|
2020-11-16 |
2023-11-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Fapを標的としたcd40アゴニストとの併用療法
|
EP4023218A1
(de)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
|
CA3202358A1
(en)
|
2020-12-16 |
2022-06-23 |
Andreas BOSSHART |
Novel slow-release prodrugs
|
EP4274658A1
(de)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit einem pd1-lag3-bispezifischen antikörper und einem bispezifischen cd20-t-zell-antikörper
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
EP4305063A1
(de)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Proteasespaltbare prodrugs
|
AU2022233791A1
(en)
|
2021-03-09 |
2023-09-28 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
JP2024508969A
(ja)
|
2021-03-09 |
2024-02-28 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規のDARPinに基づくCD33エンゲージャ
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
CN117529664A
(zh)
|
2021-06-18 |
2024-02-06 |
思芬构技术有限公司 |
用于预测脓毒症和脓毒性休克的方法
|
KR20240041912A
(ko)
|
2021-06-29 |
2024-04-01 |
베리솔 게엠베하 |
체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
WO2023175035A1
(en)
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024023368A1
(en)
|
2022-07-29 |
2024-02-01 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
WO2024126793A1
(en)
|
2022-12-15 |
2024-06-20 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
|